From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Drug | Total cost per patient* | Total QALYs per patient | Incremental cost per patient | Incremental QALYs per patient | Economic conclusion |
---|---|---|---|---|---|
PP-LAI | €3,529 | 0.840 | -€166 | 0.025 | dominant |
RIS-LAI | €3,695 | 0.815 | dominated |